IP Library Granted Patent US 9,963,432
Granted Patent B2
US 9,963,432 · App. 15/476,850 · Granted May 8, 2018

Beta-amino-isoquinolinyl amide compounds

Inventors: Jill M. Sturdivant (Chapel Hill, NC); Mitchell A. deLong (Chapel Hill, NC); Susan M. Royalty (Davis, CA)
Assignee: Aerie Pharmaceuticals, Inc.
C07D217/24C07D217/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,963,432
App. No.
15/476,850
Granted
May 8, 2018
Kind
B2
Abstract

Disclosed are alpha-aryl-beta-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. The invention further provides compositions containing isoquinoline amide compounds.

Claims (7)

1. A compound selected from:

or an enantiomer or a diastereomer, or a pharmaceutically acceptable salt thereof.

2. A composition comprising the compound of claim 1 , or an enantiomer or a diastereomer, or a pharmaceutically acceptable salt thereof, and a carrier.

3. The composition of claim 2 , wherein the carrier is saline buffered to a pH of about 5.5 to about 6.5.

4. A method for treating glaucoma in a subject in need thereof, comprising administering to the subject an effective amount of the compound of claim 1 , or an enantiomer or a diastereomer, or a pharmaceutically acceptable salt thereof.

5. A method of modulating Rho kinase activity in a cell, comprising contacting the cell with the compound of claim 1 , or an enantiomer or a diastereomer, or a pharmaceutically acceptable salt thereof, in an amount effective to modulate kinase activity.

6. The method of claim 5 , wherein the cell is in a subject.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2024
From: AERIE PHARMACEUTICALS, INC.
To: ALCON INC.
Reel/Frame 067822/0168 →
RELEASE OF SECURITY INTEREST Recorded Sep 5, 2019
From: DEERFIELD PRIVATE DESIGN FUND III, L.P.
To: AERIE PHARMACEUTICALS, INC.
Reel/Frame 050276/0807 →
SECURITY INTEREST Recorded Jul 23, 2018
From: AERIE PHARMACEUTICALS, INC.
To: DEERFIELD PRIVATE DESIGN FUND III, L.P.
Reel/Frame 046432/0307 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2017
From: STURDIVANT, JILL M.; DELONG, MITCHELL A.; ROYALTY, SUSAN M.
To: AERIE PHARMACEUTICALS, INC.
Reel/Frame 042533/0741 →
Continuity (2)
Provisional Application 62377219 · Aug 19, 2016
Related Publication 20180050990A1 · Feb 22, 2018